Brookline Capital Markets
Overview
Brookline Capital Markets is an investment bank that provides a full suite of financing solutions and strategic advice to companies in the life sciences, medical technology, and diagnostics sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Xiasma Limited | Jul 2019 | Follow-on Offering | Co-investor |
| EMulate Therapeutics | Jul 2024 | IPO | Lead |
| Betaliq, Inc. | Apr 2019 | Series A | Lead |
For institutional investors. Book with your work email.
Key People
Graham Powis
Managing Partner
Harris Lydon
Managing Partner
Samuel Wertheimer
Managing Partner & Senior Scientific Advisor
Michael Fontaine
Managing Partner, Managing Director
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Brookline Capital Markets based?
Brookline Capital Markets is headquartered in New York City, New York, United States.
When was Brookline Capital Markets founded?
Brookline Capital Markets was founded in 2013.
How many portfolio companies does Brookline Capital Markets have?
Brookline Capital Markets has 4 portfolio companies in Caplight's dataset.
What are some companies in Brookline Capital Markets's portfolio?
Portfolio companies visible on Caplight include Xiasma Limited, EMulate Therapeutics, Betaliq, Inc..
What was Brookline Capital Markets's most recent investment shown here?
Brookline Capital Markets's most recent investment in this portfolio sample was in EMulate Therapeutics in 2024.
What sectors does Brookline Capital Markets focus on?
Brookline Capital Markets focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does Brookline Capital Markets focus on?
Stage focus information for Brookline Capital Markets is not publicly available.